Coding polymorphisms of bone morphogenetic protein 2 contribute to the development of childhood IgA nephropathy

Suh,Jin-Soon; Hahn,Won-Ho; Lee,Jong   Seok; Park,Hae   Jeong; Kim,Mi-Ja; Kang,Sung   Wook; Chung,Joo-Ho; Cho,Byoung-Soo

doi:10.3892/etm.2011.195

Coding polymorphisms of bone morphogenetic protein 2 contribute to the development of childhood IgA nephropathy

Authors:
- Jin-Soon Suh
- Won-Ho Hahn
- Jong Seok Lee
- Hae Jeong Park
- Mi-Ja Kim
- Sung Wook Kang
- Joo-Ho Chung
- Byoung-Soo Cho
View Affiliations

Affiliations: Department of Pediatrics, East West Kidney Disease Research Institute, School of Medicine, Kyung Hee University, Seoul 130-701, Korea, Department of Emergency Medicine, School of Medicine, Kyung Hee University, Seoul 130-701, Korea, Kohwang Medical Research Institute, School of Medicine, Kyung Hee University, Seoul 130-701, Korea
Published online on: January 18, 2011 https://doi.org/10.3892/etm.2011.195
Pages: 337-341

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bone morphogenetic proteins (BMPs) are multi-functional growth factors belonging to the transforming growth factor β (TGFB) superfamily and are important in both preservation of kidney function and resistance to injury. BMP2 is highly regulated in the kidney, and high affinity binding sites for BMP2 have been identified in kidney epithelial cells. BMP2 has been demonstrated to play various roles in the pathogenesis of renal diseases. However, the role of the BMP2 gene in glomerulonephritis has not been previously investigated. We aimed to evaluate the association of BMP2 gene polymorphisms with immunoglobulin A nephropathy (IgAN) in children. We evaluated 187 pediatric patients with biopsy-confimed IgAN and 262 healthy controls. Two coding single nucleotide polymorphisms (cSNPs) in the BMP2 gene [rs235768 (missense, Arg190Ser) and rs1049007 (synonymous, Ser87Ser)] were selected and genotyped by direct sequencing. Genotypes of rs1049007 were associated with childhood IgAN in the codominant model II (GG vs. AA) [p=0.02; OR (95% CI), 0.16 (0.04-0.70)] and in the recessive model [p=0.0023; OR (95% CI), 0.16 (0.04-0.69)]. We also found an association between rs235768 and IgAN in the codominant model II (TT vs. AA) [p=0.01; OR (95% CI), 0.08 (0.01-0.57)] and in the recessive model [p=0.0002; OR (95% CI), 0.07 (0.01-0.55)]. After Bonferroni correction, these associations of rs235768 and rs1049007 with IgAN risk remained significant. In the haplotype analysis, the TG haplotype [p=0.01; OR (95% CI), 6.76 (1.55-29.50) in the dominant model] and AA haplotype [p=0.01; OR (95% CI), 0.08 (0.01-0.59) in the recessive model] showed associations with IgAN. The BMP2 gene may contribute to susceptibility to IgAN in Korean children.

View Figures

View References

1.	Barratt J and Feehally J: IgA nephropathy. J Am Soc Nephrol. 16:2088–2097. 2005. View Article : Google Scholar : PubMed/NCBI
2.	Barratt J, Smith AC, Molyneux K and Feehally J: Immunopathogenesis of IgAN. Semin Immunopathol. 29:427–443. 2007. View Article : Google Scholar
3.	Chen D, Zhao M and Mundy GR: Bone morphogenetic proteins. Growth Factors. 22:233–241. 2004. View Article : Google Scholar
4.	Maciel TT, Kempf H and Campos AH: Targeting bone morphogenetic protein signaling on renal and vascular diseases. Curr Opin Nephrol Hypertens. 19:26–31. 2010. View Article : Google Scholar : PubMed/NCBI
5.	Simic P and Vukicevic S: Bone morphogenetic proteins in development and homeostasis of kidney. Cytokine Growth Factor Rev. 16:299–308. 2005. View Article : Google Scholar : PubMed/NCBI
6.	Yang YL, Liu YS, Chuang LY, et al: Bone morphogenetic protein-2 antagonizes renal interstitial fibrosis by promoting catabolism of type I transforming growth factor-beta receptors. Endocrinology. 150:727–740. 2009. View Article : Google Scholar : PubMed/NCBI
7.	Iwasaki S, Tsuruoka N, Hattori A, Sato M, Tsujimoto M and Kohno M: Distribution and characterization of specific cellular binding proteins for bone morphogenetic protein-2. J Biol Chem. 270:5476–5482. 1995. View Article : Google Scholar : PubMed/NCBI
8.	Ghosh Choudhury G, Kim YS, Simon M, et al: Bone morphogenetic protein 2 inhibits platelet-derived growth factor-induced c-fos gene transcription and DNA synthesis in mesangial cells. Involvement of mitogen-activated protein kinase. J Biol Chem. 274:10897–10902. 1999.
9.	Ghosh Choudhury G, Jin DC, Kim Y, Celeste A, Ghosh-Choudhury N and Abboud HE: Bone morphogenetic protein-2 inhibits MAPK-dependent Elk-1 transactivation and DNA synthesis induced by EGF in mesangial cells. Biochem Biophys Res Commun. 258:490–496. 1999.PubMed/NCBI
10.	Pache G, Schafer C, Wiesemann S, et al: Upregulation of Id-1 via BMP-2 receptors induces reactive oxygen species in podocytes. Am J Physiol Renal Physiol. 291:F654–F662. 2006. View Article : Google Scholar : PubMed/NCBI
11.	Chan WL, Leung JC, Chan LY, Tam KY, Tang SC and Lai KN: BMP-7 protects mesangial cells from injury by polymeric IgA. Kidney Int. 74:1026–1039. 2008. View Article : Google Scholar : PubMed/NCBI
12.	Sole X, Guino E, Valls J, Iniesta R and Moreno V: SNPStats: a web tool for the analysis of association studies. Bioinformatics. 22:1928–1929. 2006. View Article : Google Scholar : PubMed/NCBI
13.	Gabriel SB, Schaffner SF, Nguyen H, et al: The structure of haplotype blocks in the human genome. Science. 296:2225–2229. 2002. View Article : Google Scholar : PubMed/NCBI
14.	Nguyen TQ, Roestenberg P, van Nieuwenhoven FA, et al: CTGF inhibits BMP-7 signaling in diabetic nephropathy. J Am Soc Nephrol. 19:2098–2107. 2008. View Article : Google Scholar : PubMed/NCBI
15.	Park Y, Kim JW, Kim DS, et al: The bone morphogenesis protein-2 (BMP-2) is associated with progression to metastatic disease in gastric cancer. Cancer Res Treat. 40:127–132. 2008. View Article : Google Scholar : PubMed/NCBI
16.	Ara J, See J, Mamontov P, et al: Bone morphogenetic proteins 4, 6, and 7 are up-regulated in mouse spinal cord during experimental autoimmune encephalomyelitis. J Neurosci Res. 86:125–135. 2008. View Article : Google Scholar : PubMed/NCBI
17.	Weiskirchen R, Meurer SK, Gressner OA, Herrmann J, Borkham-Kamphorst E and Gressner AM: BMP-7 as antagonist of organ fibrosis. Front Biosci. 14:4992–5012. 2009. View Article : Google Scholar : PubMed/NCBI
18.	Rosen V: BMP2 signaling in bone development and repair. Cytokine Growth Factor Rev. 20:475–480. 2009. View Article : Google Scholar : PubMed/NCBI
19.	Langenfeld EM, Calvano SE, Abou-Nukta F, Lowry SF, Amenta P and Langenfeld J: The mature bone morphogenetic protein-2 is aberrantly expressed in non-small cell lung carcinomas and stimulates tumor growth of A549 cells. Carcinogenesis. 24:1445–1454. 2003. View Article : Google Scholar : PubMed/NCBI
20.	Kleeff J, Maruyama H, Ishiwata T, et al: Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo. Gastroenterology. 116:1202–1216. 1999. View Article : Google Scholar : PubMed/NCBI
21.	Liu C, Tian G, Tu Y, Fu J, Lan C and Wu N: Expression pattern and clinical prognostic relevance of bone morphogenetic protein-2 in human gliomas. Jpn J Clin Oncol. 39:625–631. 2009. View Article : Google Scholar : PubMed/NCBI
22.	Baelde HJ, Eikmans M, Doran PP, Lappin DW, de Heer E and Bruijn JA: Gene expression profiling in glomeruli from human kidneys with diabetic nephropathy. Am J Kidney Dis. 43:636–650. 2004. View Article : Google Scholar : PubMed/NCBI
23.	Dalfino G, Simone S, Porreca S, et al: Bone morphogenetic protein-2 may represent the molecular link between oxidative stress and vascular stiffness in chronic kidney disease. Atherosclerosis. 211:418–423. 2010. View Article : Google Scholar : PubMed/NCBI
24.	Sieber C, Kopf J, Hiepen C and Knaus P: Recent advances in BMP receptor signaling. Cytokine Growth Factor Rev. 20:343–355. 2009. View Article : Google Scholar : PubMed/NCBI